NCT02143570View on ClinicalTrials.gov

Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Overactive Bladder
Interventions
DRUG

Darifenacin

Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.

PROCEDURE

Physiotherapy

All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.

Trial Locations (1)

2341131

Hospital Carlos Van Buren, Valparaíso

All Listed Sponsors
collaborator

Recalcine (GynoPharm)

UNKNOWN

lead

Universidad de Valparaiso

OTHER

NCT02143570 - Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women | Biotech Hunter | Biotech Hunter